ASND Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ascendis Pharma A/S (ASND) is a good buy for a beginner investor with a long-term investment horizon and $50,000-$100,000 available for investment. The stock has strong growth potential driven by its innovative product pipeline, positive analyst ratings, and bullish technical indicators. Despite some financial challenges, the long-term growth trajectory and market opportunities outweigh the risks.
The technical indicators are bullish. The MACD is positive and contracting, indicating potential upward momentum. The RSI is neutral at 60.252, and the moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 247.947 and 256.02, while support levels are at 234.879 and 221.81.
Analysts have consistently raised price targets, with the latest targets ranging from $256 to $332, reflecting confidence in the company's growth trajectory.
The recent FDA approval of Yuviwel and orphan drug exclusivity for TransCon CNP are significant milestones.
Strong growth potential for Yorvipath and Yuviwel, with Yorvipath expected to become a multi-billion-dollar drug.
Revenue growth of 42.31% YoY in Q4 2025 indicates strong sales momentum.
Hedge funds are selling, with a 565.41% increase in selling activity over the last quarter.
The company reported a net income loss of -$33.56M in Q4 2025, with EPS and gross margin declining YoY.
Insider trading activity is neutral, with no significant buying trends.
In Q4 2025, revenue grew by 42.31% YoY to $247.5M, driven by strong product adoption. However, net income dropped by -12.76% YoY to -$33.56M, and EPS declined by -14.06% YoY to -0.55. Gross margin also slightly decreased to 90.47%. While the company is experiencing losses, its revenue growth and product pipeline suggest long-term potential.
Analysts are overwhelmingly bullish on ASND, with multiple firms maintaining Buy or Outperform ratings and raising price targets. The average price target is significantly above the current price, with the highest target at $332. Analysts highlight the company's innovative TransCon platform and strong growth potential for Yorvipath and Yuviwel as key drivers.
